ACROBiosystems Launches SAFENSURE™: Advanced Safety Testing Solution Powering Biologics from Development to Commercialization

ACROBiosystems announces the launch of its new brand — SAFENSURE™, a specialized safety testing solution designed to meet the rigorous demands of global biopharmaceutical standards. Fully compliant with major pharmacopeias and international regulations, SAFENSURE™ offers validated assay kits for critical safety evaluations in biologics manufacturing, including endotoxin detection, mycoplasma testing, and sterility verification, ensuring comprehensive product safety and regulatory compliance throughout the entire production lifecycle.

The Essence of SAFENSURE™: Safety Meets Assurance

The name SAFENSURE™ embodies ACROBiosystems' dual commitment: "Safe" represents uncompromising product safety for therapeutics, while "Ensure" delivers reliable, standardized solutions for contamination control.

SAFENSURE™ delivers rigorously tested safety solutions with unmatched consistency (<15% batch variability), full compliance with global standards (USP/EP/ChP), and reliable 1-3 day worldwide delivery. This new brand reinforces ACROBiosystems commitment to pharmaceutical-grade quality control through validated testing protocols that meet all international regulatory requirements.

Notably, the Endotoxin Detection Platform carries both functional and social responsibility significance. Compared to conventional LAL assays, this kit provides improved accuracy, eliminates interference from Factor G pathways, and delivers more consistent, reproducible results - fully aligned with global regulatory trends toward sustainability and animal-free testing.

SAFENSURE™: The Safety Testing Pillar of Resilient Supply's CMC Ecosystem

Positioned under ACROBiosystems' Resilient Supply brand—a dedicated CMC platform delivering flexible, resilient, lower-risk, and high-quality solutions with enhanced professional support—SAFENSURE™ completes the safety testing pillar alongside CMC production brands (Cellectra™, ActiveMax™, GENIUS™, GENPOWER™, CytoPak™, CellThera™) and CMC QC brands (resDetect™, etc.), forming a fully integrated solution for biopharmaceutical development and manufacturing.

About ACROBiosystems Group

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in over 10 different cities within the United States, Switzerland, England and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.